Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC.

Hajighasemlou, Saieh; Nikbakht, Mohsen; Pakzad, Saeedreza; Muhammadnejad, Samad; Gharibzadeh, Safoora; Mirmoghtadaei, Milad; Zafari, Fariba; Seyhoun, Iman; Ai, Jafar; Verdi, Javad.

Afiliação

Hajighasemlou S; Tehran University of Medical Sciences (TUMS), Tissue Engineering & Applied Cell Sciences, Tehran, Iran.
Nikbakht M; Iran Ministry of Health and Medical Education, Food and Drug Control Laboratory (FDCL), Tehran, Iran.
Pakzad S; Tehran University of Medical Sciences, Hematology, Oncology & Stem Cell Transplantation Research Center, Tehran, Iran.
Muhammadnejad S; Iran Ministry of Health and Medical Education, Food and Drug Control Laboratory (FDCL), Tehran, Iran.
Gharibzadeh S; Tehran University of Medical Sciences (TUMS), Cancer Biology Research Center Tehran, Tehran, Iran.
Mirmoghtadaei M; Pasteur Institute of Iran, Department of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Tehran, Iran.
Zafari F; Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Seyhoun I; Qazvin University of Medical Science, Cellular and Molecular Research Center, Qazvin, Iran.
Ai J; Tehran University of Medical Sciences (TUMS), Tissue Engineering & Applied Cell Sciences, Tehran, Iran.
Verdi J; Tehran University of Medical Sciences (TUMS), Tissue Engineering & Applied Cell Sciences, Tehran, Iran.

Evid Based Complement Alternat Med ; 2020: 9602728, 2020.

Article em En | MEDLINE | ID: mdl-32617114

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article